Laurus Labs acquires 87.59% stake in Laurus Bio Private
Laurus Labs concluded the acquisition by securing the remaining 8,333 equity shares from the promoter group shareholders
Laurus Labs concluded the acquisition by securing the remaining 8,333 equity shares from the promoter group shareholders
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol
Jan Ausahdhi exhibited demonstration stall during 42nd India International Trade Fair to spread awareness
Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
The countrywide initiative aims to spread awareness, educate the public & ensure that no one is left behind in the fight against respiratory diseases
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
Subscribe To Our Newsletter & Stay Updated